From the company’s immune-oncology portfolio, GBR 1342 is an investigational new drug.

The share price of Glenmark Pharma  advanced over a percent intraday Friday. This was observed as the company started clinical trial for anti-myeloma drug.

The company stated in filing that the first patient was dosed in a phase-1 clinical trial of GBR 1342. This is an investigational antibody for treatment of multiple myeloma.

From the company’s immune-oncology portfolio, GBR 1342 is an investigational new drug.

The company also stated that this first-in-human, open-label study’s primary objective is to review the safety and tolerability of increasing doses of GBR 1342 in multiple myeloma patients until a maximum tolerated dose is reached.

It was informed that the additional study objectives also embrace the assessment of biomarkers, immunogenicity and additional measures of anti-tumour activity.

In just the last year, three of the biologics of company have begun clinical trials. This is a testament to the outstanding progress made by the global R&D workforce. Out of three, two are immuno-oncology agents according to the President and Chief Medical Officer of the company, Fred Grossman.

Earlier, the US health regulator had cleared Glenmark’s investigational new drug application to initiate phase-1 study of GBR 1342 in May.

On the BSE, the stock price was quoting at Rs 536.50, up Rs 3.85, or 0.72 percent at 12:10 hours IST.

Leave a Reply

Your email address will not be published. Required fields are marked *